Clinical Players and Healthcare Payers: Aligning Perspectives on the Cost–Effectiveness of Next-Generation Sequencing in Oncology

Doble, Brett; Lorgelly, Paula

doi:10.2217/pme.14.81

Cited by 7 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Readily available and cost‐effective gene sequencing will likely become a valuable tool in achieving precision medicine treatment options, especially for cancer patients, where genetic mutations play a critical role in the onset of the disease . However, there remains a number of issues needing attention with regard to the application of NGS technology for the treatment of cancer in current healthcare systems, such as the effectiveness of molecular targeted therapy based on patients’ genetic information, and the reimbursement of the costs . These concerns are beginning to be addressed, but there is a need for a more robust and comprehensive economic evaluations of NGS technology as a diagnostic option in cancer care.…”

Section: Discussionmentioning

confidence: 99%

Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness

et al. 2018

View full text Add to dashboard Cite

Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Over time, medicine and healthcare models have evolved towards a practice that is technically feasible, economically valuable [ 4 , 5 ], and culturally, ethically, and socially accepted. In this evolution, personalized care could be the key.…”

mentioning

confidence: 99%

Personalized Care and Treatment Compliance in Chronic Conditions

Fernandes

Teixeira

Godinho

2022

JPM

View full text Add to dashboard Cite

show abstract

“…Over time, new paradigms of medicine and healthcare have been defined and an approach that genuinely tends toward the single person is technically feasible, economically valuable [1,2] and culturally, ethically and socially accepted: with time, it will more and more unethical and uneconomic to deliver nonpersonalized services considering the inefficacy, side effects and high costs of some standard treatment [3,4].…”

mentioning

confidence: 99%

The Evolution of Personalized Healthcare and the Pivotal Role of European Regions in its Implementation

et al. 2021

View full text Add to dashboard Cite

Personalized medicine (PM) moves at the same pace of data and technology and calls for important changes in healthcare. New players are participating, providing impulse to PM. We review the conceptual foundations for PM and personalized healthcare and their evolution through scientific publications where a clear definition and the features of the different formulations are identifiable. We then examined PM policy documents of the International Consortium for Personalised Medicine and related initiatives to understand how PM stakeholders have been changing. Regional authorities and stakeholders have joined the race to deliver personalized care and are driving toward what could be termed as the next personalized healthcare. Their role as a key stakeholder in PM is expected to be pivotal.

show abstract

Clinical Players and Healthcare Payers: Aligning Perspectives on the Cost–Effectiveness of Next-Generation Sequencing in Oncology

Cited by 7 publications

References 19 publications

Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness

Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness

Personalized Care and Treatment Compliance in Chronic Conditions

The Evolution of Personalized Healthcare and the Pivotal Role of European Regions in its Implementation

Contact Info

Product

Resources

About